Last reviewed · How we verify
Apomorphine Sublingual Film
At a glance
| Generic name | Apomorphine Sublingual Film |
|---|---|
| Also known as | Kynmobi |
| Sponsor | William Ondo, MD |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- SL-START - SubLingual Apomorphine Schemes of TitrAtion in Real-world Treatment
- Open-Label Phase 3 Study to Examine the Long-Term Safety, Tolerability and Efficacy of APL-130277 for the Acute Treatment of "OFF" Episodes in Patients With Parkinson's Disease (PHASE3)
- Sublingual Apomorphine in Refractory Restless Legs Syndrome (PHASE4)
- A Study That Compares the Extent to Which Apomorphine Becomes Available in the Body After Taking Either an Investigational Drug Containing Apomorphine or Apomorphine That is Injected Under the Skin in People With PD Complicated by "OFF" Episodes (PHASE2)
- Efficacy, Safety and Tolerability Study of APL-130277 for the Acute Treatment of OFF Episodes in Patients With Parkinson's Disease (PHASE3)
- A Study to Examine APL-130277 in Patients With Parkinson's Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Apomorphine Sublingual Film CI brief — competitive landscape report
- Apomorphine Sublingual Film updates RSS · CI watch RSS
- William Ondo, MD portfolio CI